Czech Biotech Database

SINGAPORE, April 15, 2019 /PRNewswire/ -- Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies targeting solid tumors, today announced that it has entered into an agreement with Merck (known as MSD outside the US and... Read more ››

By: PR Newswire Association LLC. - 16 Apr 2019

Tessa Therapeutics Announces Collaboration with MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer

SINGAPORE, April 16, 2019 /PRNewswire/ -- Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies targeting solid tumors, today announced that it has entered into an agreement with MSD (tradename of Merck & Co., Inc.,... Read more ››

By: PR Newswire Association LLC. - 16 Apr 2019

Looking for companies outside of Czech Republic?

Browse our global Life Sciences lead sourcing platform Biotechgate for company information, product pipelines, licensing opportunities, management details and much more.

Partners

Upcoming Life Sciences Events

September 2019
- Dusseldorf: 5th Annual Pre-Filled Syringes & Injectables Summit
- Munich: The Biotech & Pharma Summit: Drug Delivery & Formulation
- Brussels: The Pharma Forecasting Course

See Events »

Add an Event »

Latest company news

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products
29 Aug 2019 (Nasdaq / GlobenewsWire)

Financial calendar 2019/20
26 Aug 2019 (Nasdaq / GlobenewsWire)

Managers' transactions
01 Jul 2019 (Nasdaq / GlobenewsWire)

News in the Life Sciences Industry

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Financial calendar 2019/20

Managers' transactions

Chr. Hansen Holding A/S - Major shareholder announcement from The Capital Group Companies, Inc.

Managers' transactions

Interim Report September 1, 2018 - May 31, 2019

Changes to the financial calendar 2018/19

Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer

Tessa Therapeutics Announces Collaboration with MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer

Managers’ transactions

Managers’ transactions

Interim report September 1, 2018 – February 28, 2019

Chr. Hansen and Lonza establish a 50/50 joint venture to pioneer the emerging market for live biotherapeutic products

Looking for companies outside of Czech Republic?

Partners

Upcoming Life Sciences Events

Latest company news